These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11815576)

  • 1. Beta-lactam modification of the bacteraemic profile and its relationship with mortality in a pneumococcal mouse sepsis model.
    Yuste J; Jado I; Fenoll A; Aguilar L; Giménez MJ; Casal J
    J Antimicrob Chemother; 2002 Feb; 49(2):331-5. PubMed ID: 11815576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model.
    Casal J; Aguilar L; Jado I; Yuste J; Giménez MJ; Prieto J; Fenoll A
    Antimicrob Agents Chemother; 2002 May; 46(5):1340-4. PubMed ID: 11959566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci.
    Rodríguez-Cerrato V; Del Prado G; Huelves L; Naves P; Ruiz V; García E; Ponte C; Soriano F
    Int J Antimicrob Agents; 2010 Jun; 35(6):544-9. PubMed ID: 20303716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model.
    Yuste J; Jado I; Giménez MJ; Aguilar L; Molero F; Fenoll A; Casal J
    Clin Exp Immunol; 2002 Jun; 128(3):411-5. PubMed ID: 12067294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality.
    Fernández Guerrero ML; Ramos JM; Marrero J; Cuenca M; Fernández Roblas R; de Górgolas M
    Int J Infect Dis; 2003 Mar; 7(1):46-52. PubMed ID: 12718810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus.
    Letrado P; Corsini B; Díez-Martínez R; Bustamante N; Yuste JE; García P
    Future Microbiol; 2018 Sep; 13(11):1215-1223. PubMed ID: 30238774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal LytA autolysin, a potent therapeutic agent in experimental peritonitis-sepsis caused by highly beta-lactam-resistant Streptococcus pneumoniae.
    Rodríguez-Cerrato V; García P; Huelves L; García E; Del Prado G; Gracia M; Ponte C; López R; Soriano F
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3371-3. PubMed ID: 17576844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.
    Jado I; López R; García E; Fenoll A; Casal J; García P;
    J Antimicrob Chemother; 2003 Dec; 52(6):967-73. PubMed ID: 14613958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced decrease of blood colony counts by specific anti-pneumococcal antibodies in the presence of sub-inhibitory concentrations of amoxicillin.
    Yuste J; Giménez MJ; Jado I; Fenoll A; Aguilar L; Casal J
    J Antimicrob Chemother; 2001 Oct; 48(4):594-5. PubMed ID: 11581248
    [No Abstract]   [Full Text] [Related]  

  • 10. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.
    Yu VL; Chiou CC; Feldman C; Ortqvist A; Rello J; Morris AJ; Baddour LM; Luna CM; Snydman DR; Ip M; Ko WC; Chedid MB; Andremont A; Klugman KP;
    Clin Infect Dis; 2003 Jul; 37(2):230-7. PubMed ID: 12856216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia.
    Loeffler JM; Djurkovic S; Fischetti VA
    Infect Immun; 2003 Nov; 71(11):6199-204. PubMed ID: 14573637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia.
    Cremers AJ; Sprong T; Schouten JA; Walraven G; Hermans PW; Meis JF; Ferwerda G
    J Antimicrob Chemother; 2014 Aug; 69(8):2258-64. PubMed ID: 24729585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study.
    Batard E; Juvin ME; Jacqueline C; Bugnon D; Caillon J; Potel G; Drugeon HB
    Antimicrob Agents Chemother; 2005 Jan; 49(1):464-6. PubMed ID: 15616338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Zhang C; Nightingale CH; Nicolau DP
    Chemotherapy; 2004 Apr; 50(1):11-6. PubMed ID: 15084799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France.
    Decousser JW; Pina P; Picot F; Allouch PY
    Eur J Clin Microbiol Infect Dis; 2003 Sep; 22(9):561-5. PubMed ID: 12942341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in-vivo efficacy by in-vitro early bactericidal activity with oral beta-lactams, in a dose-ranging immunocompetent mouse sepsis model, using strains of Streptococcus pneumoniae with decreasing susceptibilities to penicillin.
    Pérez-Trallero E; Alkorta M; Giménez MJ; Vicente D; Aguilar L
    J Chemother; 2001 Apr; 13(2):118-25. PubMed ID: 11330357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal synergism between daptomycin and the phage lysin Cpl-1 in a mouse model of pneumococcal bacteraemia.
    Vouillamoz J; Entenza JM; Giddey M; Fischetti VA; Moreillon P; Resch G
    Int J Antimicrob Agents; 2013 Nov; 42(5):416-21. PubMed ID: 23992647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.